CN102653533A - Total synthesis method of mangostin - Google Patents
Total synthesis method of mangostin Download PDFInfo
- Publication number
- CN102653533A CN102653533A CN2011103020408A CN201110302040A CN102653533A CN 102653533 A CN102653533 A CN 102653533A CN 2011103020408 A CN2011103020408 A CN 2011103020408A CN 201110302040 A CN201110302040 A CN 201110302040A CN 102653533 A CN102653533 A CN 102653533A
- Authority
- CN
- China
- Prior art keywords
- reaction
- formula
- solvent
- compound
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)=CCc(c(O)c12)c(*)cc1Oc1cc(*)c(*)c(CC=C(C)C)c1C2=O Chemical compound CC(C)=CCc(c(O)c12)c(*)cc1Oc1cc(*)c(*)c(CC=C(C)C)c1C2=O 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of chemical synthesis, in particular relates to a synthesis method of a natural product mangostin which is shown in the formula (I) and has good anti-tumor activity, anti-inflammation activity and anti-bacterial activity. The method provided by the invention comprises the following steps of: taking 2,4,5-trialkoxy benzoic acid and 1,3,5-trialkoxy benzene as initial raw materials; carrying out acyl chlorination, Friedel-Crafts acylation and cyclization to prepare a key intermediate 1,3,6,7-tetraalkoxy xanthone; and then, carrying out dealkylation, allylation, Claisen rearrangement, methylation, oxidation reaction, WITTING reaction and dealkylation reaction so as to prepare the mangostin.
Description
Technical field
The invention belongs to the field of chemical synthesis, be specifically related to the compound method of the natural product mangostin shown in a kind of formula (I) with good resistance tumor promotion, anti-inflammatory, anti-microbial activity.
Background technology
Mangosteen (Garcinia mangostana L) is a kind of plant that is distributed widely in the torrid areas, South East Asia; Its pericarp and bark are used to treat diseases such as heating, dysentery, wound infection by the local resident as traditional Chinese medicine have history for many years; And its fruit has abundant nutritive value; Title (Phytochemistry.1997,44:191-214 that the king of fruit is arranged; J Agric Food Chem.2007,55:7689-94; J Agric Food Chem.2002,50:7449-7454).Natural Medicine Chemistry is discovered a series of secondary metabolites that contain in this kind of plant of mangosteen, like the xanthone compound of ether ring type of closing and isopentene base class, confirms to have anticancer, anti-inflammatory, multiple biological activity such as antibiotic after deliberation.Particularly from peel of Carcinia mangostana L., separate and obtain a series of Mangostin compounds (Chinese names: mangostin): α-mangostin with isopentene group structure; β-mangostin, γ-mangostin and β-mangostin-OMe have extensive and good biological activity.In recent years; The research group at Japan scholar Yukihiro Akao and his place separation and Extraction from the pericarp of mangosteen and tree root obtains α-mangostin; β-mangostin; Four compounds of γ-mangostin and β-mangostin-OMe, and confirm that first three compound has the activity of resisting human colon cancer cell (DLD-1) very by force, IC
50Value between 7.1~8.1uM (Int J Mol Sci.2008,9:355-370).Discovery γ-mangostin such as American scholar G.C.L.Ee have the good restraining effect to cancerous cell line CEM-SS cell, IC
50The value for 4.7uM (Nat Pro Sci.2006,12:138-143).A plurality of xanthone compounds with isopentene group constitutional features that handles such as Ah-Reum Han obtain from natural product have carried out the external activity screening; Find that α-mangostin and β-mangostin have the activity of good inhibition CCL188 HT-29, IC
50Value be respectively 1.7uM and 2.3uM (J Nat Prod.2009,72:2028-2031).
In view of mangostin unique chemical structure and biological activity, has the significance of carrying out composition optimizes and pharmacodynamic study in a deep going way.At present; Mangostin mainly obtains through two kinds of approach: one of which, and extraction separation obtains from natural product, and still existing extraction and separation method complex steps, process are very complicated, the cycle is very long; And yield extremely low (Phytomedicine.2005,12:203-208; J Nat Prod, 2002,65:761-763; Phytochemistry, 1993,32:1245-1251); Its two, obtain through complete synthesis and semi-synthetic means.
Complete synthesis:
1981, Hiok-Huang Lee etc. proposed the method for the synthetic Mangostin of a kind of segmented first, has successfully obtained 3; 6,7-trimethoxy-γ-mangostin and 3,6-dimethoxy-γ-mangostin; This route has certain study on the synthesis to be worth, but step is numerous and diverse, and yield is extremely low, and (J C S.Perkin I.1981; 3205-3213), its synthetic route is following:
2002, Japanese scholar Kazuhiko Iikubo is complete synthesis α-mangostin in the laboratory first.This route of Kazuhiko Iikubo has been selected the segmented synthesis method equally, and earlier synthetic fragment 1 and fragment 2 are constructed isopentene group functional group respectively on two fragments 1 and 2; Amalgamation is together more at last; Totally 21 steps reaction, yield is less than 3% (Tetrahedron Lett, 2002; 43:291-293), its synthetic route is following:
Reagent and condition: (a) BnBr, K
2CO
3, DMF, rt, 96%; (b) mCPBA, CH
2Cl
2, rt; 6M HCl, MeOH, rt, 95% in two steps; (c) Br
2, CHCl
3, rt, 84%; (d) allyl bromide, K
2CO
3, DMF, rt, 80%; (e) 160 ℃, 73%; (f) Mel, K
2CO
3, DMF, rt, 87%; (g) OsO
4, NalO
4, Et
2O/H
2O (1/1), rt, 95%; (h) iPrPh
3P
+I
-, nBuLi, THF, 0 ℃, 72%.
Reagent and condition: (a) NaH, MOMCl, DMF, rt, 96%; (b) nBuLi; Prenyl bromi de, THF, 0 ℃, 89%; (c) nBuLi; (EtO)
2CO, THF, 0 ℃, 95%; (d) CSA, MeOH, 60 ℃, 100%; (e) TBSCl, DMAP, Et
3N, DMF, rt, 100%; (f) DI BAL-H, toluene ,-78 ℃, 78%; (g) I BX, toluene/DMSO (1/1), rt, 76%; (h) NaH, MOMCl, CH
2Cl
2, rt, 65%; (i) TBAF, THF, 0 ℃, 100%; (j) BnBr, K
2CO
3, DMF, rt, 98%.
Reagent and condition: (a) nBuLi, THF ,-78 ℃, 49%; (b) I BX, toluene/DMSO (1/1), rt, 76%; (c) 10Pd/C, HCO
2NH
4, acetone, rt, 63%; (d) PPh
3, CCl
4, THF, rt, then silica gel, 43%
Semi-synthetic
γ-mangostin content in the mangosteen plant is rare, at present also not to its complete synthesis bibliographical information.Except extraction separation, it is semi-synthetic to utilize isolating natural product to carry out, and is the main means that obtain γ-mangostin.α-mangostin that domestic scholars Wei Yong cutting edge of a knife or a sword etc. utilizes extraction separation to obtain, through the demethylation of hydroiodic acid HI, high yield obtained γ-mangostin, (assay office, 2008,7:65-67), synthetic route is following:
Mainly have disadvantage in the above-mentioned compound method: 1. method one all is that reactions step is long through segmented synthetic method with method two, and yield is extremely low, severe reaction conditions, and most of reaction cost is too high, is difficult to adapt to scale operation; 2. method three is that to utilize isolating natural product to carry out semi-synthetic, but existing separation method complex steps, and the cycle is very long, and yield is extremely low, thereby the source is very limited.
The present invention is with 2,4,5-tri-alkoxy phenylformic acid and 1,3, and 5-tri-alkoxy benzene is starting raw material; Through chloride, friedel-crafts acylation, annulation prepares key intermediate: 1,3; 6,7-four alkoxyl group xanthone, again through dealkylation, allylate; Claisen rearrangement, methyl-etherified, oxidizing reaction, WITTING reaction and dealkylation reaction make mangostin.Compare with aforesaid method, involved in the present invention to reaction all be typical reaction, the raw material of employing is cheap and easy to get, reactions step is short, yield is higher.
Summary of the invention
The object of the present invention is to provide the compound method of the mangostin shown in a kind of formula (I), comprise the steps:
1. in following formula (III), formula (IV), formula V, formula (VI), formula (VII), formula (VIII), formula (IX), formula (X), formula (XI) and formula (XII), R
1R
2Identical or different, the independent separately C that represents
1~C
5Direct-connected alkane.
(1) with 2,4 shown in (IV), 5-tri-alkoxy phenylformic acid is a raw material, makes 2,4 shown in the formula V, 5-tri-alkoxy Benzoyl chloride 99min. with the halogenating agent reaction:
This reaction is characterised in that halogenating agent is selected from one or more in thionyl chloride, oxalyl chloride, phosphorus trichloride or the phosphorus pentachloride, and reaction solvent is methylene dichloride or DMF, and temperature of reaction is the boiling temperature of solvent for use, and the reaction times is 18~24 hours;
(2) under Lewis acid condition, under Lewis acid condition, the formula V compound makes formula (VI) compound with equal tri-alkoxy benzene reaction:
This reaction is characterised in that; Lewis acid is selected from one or more in boron trifluoride, aluminum chloride, alchlor or the zinc chloride; Reaction solvent is a kind of in dithiocarbonic anhydride, oil of mirbane, anhydrous diethyl ether, the ethylene dichloride; Temperature of reaction is the boiling temperature of solvent for use, and the reaction times is 24~48 hours;
(3) formula (VI) compound makes the compound shown in the formula (VII) at alkaline condition refluxed Cheng Huan:
This reaction is characterised in that; Alkaline reagents is selected from one or more in salt of wormwood, yellow soda ash, sodium hydroxide, Pottasium Hydroxide, sodium hydrogencarbonate or the saleratus; Solvent is the mixture of methyl alcohol and water, and temperature of reaction is the boiling temperature of mixed solvent, and the reaction times is 20~24 hours;
(4) formula (VII) compound makes the compound shown in the formula (VIII) through the dealkylation reaction:
This reaction is characterised in that the dealkylation reaction reagent is selected from one or more in sulfuric acid, hydroiodic acid HI, Hydrogen bromide/acetic acid, the boron tribromide, and temperature of reaction is the boiling temperature of solvent for use, and the reaction times is 3.5~20 hours;
(5) under alkaline condition, formula (VIII) compound makes the compound shown in the formula (IX) through the allylate reaction:
This reaction is characterised in that; The allylate reaction reagent is selected from one or more in allyl acetate, chlorallylene, allyl bromide 98, the allyl alcohol; Alkaline reagents is selected from one or more in yellow soda ash, salt of wormwood, sodium hydroxide, Pottasium Hydroxide, sodium hydrogencarbonate or the saleratus; Reaction solvent is an acetone, and temperature of reaction is 40~56 ℃, and the reaction times is 18~24 hours;
(6) formula (IX) compound makes compound shown in the formula (X) in high temperature, polar solvent condition refluxed:
This reaction is characterised in that, polar solvent is selected from a kind of in toluene, phenyl ether, N, accelerine or N, the N-Diethyl Aniline, and temperature of reaction is the boiling temperature of solvent for use, and the reaction times is 3.5~6 hours;
(7) under alkaline condition, formula (X) compound and methyl-etherified reagent react make the compound shown in the formula (XI):
This reaction is characterised in that; Methyl-etherified reagent is selected from a kind of in methyl-sulfate, methyl iodide, the chloromethyl ether; Alkaline reagents is selected from one or more in yellow soda ash, salt of wormwood, sodium hydroxide or the Pottasium Hydroxide; Reaction solvent is a kind of in methyl alcohol, ethanol, acetone or the ether, and temperature of reaction is the suitable temp between the boiling temperature of room temperature and solvent for use, and the reaction times is 0.8~4 hour;
(8) formula (XI) compound and oxidant reaction make the compound shown in the formula (XII):
This reaction is characterised in that; Oxygenant is selected from a kind of in a kind of and lead tetraacetate in the wet silver acetate of potassium permanganate, osmium tetroxide, potassium osmate or iodo-, sodium periodate, the periodic acid; The mixed solvent of the solvent of the preferred middle polarity of solvent, the trimethyl carbinol and water; Its volume ratio is preferably 3: 1: 1, and temperature of reaction is 25 ℃, and the reaction times is 8 hours;
(9) under coldcondition, formula (XII) compound and WITTING reagent (II) reaction make formula (III) compound, work as R
1=R
2=-CH
3The time, make β-mangostin-OMe:
This reaction is characterised in that answering solvent is THF or ethers, and temperature of reaction is-78 ℃~0 ℃, and the reaction times is 6 hours;
(10) under hot conditions, formula (III) compound makes α-mangostin with the inorganic salt reaction that contains cyanide ion:
This reaction is characterised in that, the inorganic salt that contain cyanide ion are selected from one or more in sodium cyanide, Potssium Cyanide, the cuprous cyanide, the preferred DMSO of reaction solvent, and temperature of reaction is 140~200 ℃, the reaction times is 6~8 hours;
(11) under Lewis acid condition, α-mangostin makes γ-mangostin through demethylation reaction:
This reaction is characterised in that; Demethylation reaction carries out under Lewis acid condition, and wherein Lewis acid is selected from a kind of in aluminum chloride or the alchlor, and catalyzer is selected from the inorganic salt that contain iodide ion; Reaction solvent is selected from chloroform, methylene dichloride, 1; 2-ethylene dichloride, temperature of reaction are the boiling temperature of solvent for use, and the reaction times is 2 hours.
2. key intermediate (II) synthetic comprises following synthesis step:
(1) at high temperature, different propane of halo and triphenyl phosphorus sealed reaction get the bullion of halo sec.-propyl triphenylphosphine:
This reaction is characterised in that temperature of reaction is 120 ℃~150 ℃, and the reaction times is 12~24 hours;
(2) step (1) gained bullion recrystallization is obtained the halo sec.-propyl triphenylphosphine of purifying, this step is characterised in that preferred ether of the solvent of recrystallization and ethanol mixed solvent, its volume ratio are 100: 3~20: 3;
(3) with step (2) gained halo sec.-propyl triphenylphosphine and highly basic react triphenyl sec.-propyl phosphine alkane:
This reaction is characterised in that; Highly basic is selected from one or more in sodium ethylate, potassium tert.-butoxide, sodium hydride, sodium amide, diisopropylamino lithium, n-Butyl Lithium, the phenyl lithium; Halo sec.-propyl triphenylphosphine and alkaline mol ratio are 1: 1~1: 1.4; Reaction solvent is a kind of in ether or the THF, and temperature of reaction is-78 ℃~0 ℃, and the reaction times is 1 hour;
(4) step (1) is to step (3), and the different propane of halo is selected from a kind of in bromo propane or the chloroisopropane, and halo sec.-propyl triphenylphosphine is selected from a kind of in bromo sec.-propyl triphenylphosphine or the chloro sec.-propyl triphenylphosphine.
Embodiment
In order further to illustrate the present invention, provide some embodiment below, these embodiment are illustrative fully, they only are used for the present invention is specifically described, and are not to be understood that to be limitation of the present invention.
Embodiment 1
2,4, the preparation of 5-trimethoxy-benzoyl chloride (V):
With 2,4,5-trimethoxybenzoic acid 4.24g (0.02mol) is dissolved in the 50mL methylene dichloride, adds oxalyl chloride 6mL, stirring at room, and the evaporated under reduced pressure solvent directly drops into next step reaction.
Embodiment 2
2-hydroxyl-2 ', 4,4 ', 5 ', 6-pentamethoxyl UVNUL MS-40 (VIb) and 2-hydroxyl-2 ', 4,4 ', 5 ', the preparation of 6-pentamethoxyl UVNUL MS-40 (VIa):
At the solid 2,4 that embodiment 1 makes, add the 60mL ether in the 5-trimethoxy-benzoyl chloride (V); Slowly add 1,3,5-trimethoxy-benzene 3.30g (0.018mol); Add aluminum chloride 9.35g (0.07mol) in batches, reaction solution becomes blood red, has block sticky solid to occur.Remove ice bath, refluxed 36 hours.Use ethyl acetate extraction, purification by silica gel column chromatography (petrol ether/ethyl acetate=4: 1) gets yellow particle shape solid 2-hydroxyl-2 ', 4; 4 ', 5,6 '-pentamethoxyl UVNUL MS-40 (VIa) 1.3g, productive rate 20%; Compound 2-hydroxyl-2 ', 4,4 '; 5 ', 6-pentamethoxyl UVNUL MS-40 (VIb) 1.5g, productive rate 22%.
Compound VI a
1H-NMR(300MHz,CDCl
3):δ3.72(s,6H,C
4-OCH
3,C
5-OCH
3),δ3.86(s,3H,C
4’-OCH
3),δ3.88(s,6H,C
2’-OCH
3,C
6’-OCH
3),δ6.55(s,1H,C
6-H),δ6.78(d,2H,C
3’-H,C
5’-H),δ7.03(d,1H,C
6-H),δ7.43(s,1H,C
6-H),δ12.46(s,1H,C
2-OH);
EI-MS(m/z):348(M
+),333,317,180,152.
Compound VI b
1H-NMR(300MHz,CDCl
3):δ3.54(s,3H,C
4-OCH
3),δ3.62(s,6H,C
2-OCH
3,C
6-OCH
3),δ3.85(s,3H,C
5’-OCH
3),δ3.89(s,3H,C
6-OCH
3),δ3.99(s,3H,C
4’-OCH
3),δ3.85(s,3H,C
2’-OCH
3),δ6.06(s,6H,C
3-H,C
5-H),δ6.37(s,3H,C
3’-H,δ7.34(s,3H,C
6’-H);
EI-MS(m/z):362(M
+),345,331,317,195,151.
Embodiment 3
1,3,6, the preparation of 7-tetramethoxy xanthone (VII):
With 2-hydroxyl-2 ', 4,4 ', 5,6 '-pentamethoxyl UVNUL MS-40 (VIa) or 2-hydroxyl-2 '; 4,4 ', 5 ', 6-pentamethoxyl UVNUL MS-40 (VIb) 3.48g (0.01mol) altogether is dissolved in the 60mL methyl alcohol, adds 90mL water and 6.0g (0.15mol) sodium hydroxide; 80 ℃ were refluxed 24 hours, were cooled to room temperature, a large amount of faint yellow cotton-shaped solids occurred, and recrystallizing methanol after the suction filtration drying obtains off-white color amorphous solid 1; 3,6,7-tetramethoxy xanthone (VII) 2.76g, yield 87.3%.
1H-NMR(300MHz,CDCl
3):δ3.90(s,3H,C
3-OCH
3),δ3.97(s,6H,C
6-OCH
3,C
7-OCH
3),δ3.98(s,3H,C
1-OCH
3),δ6.34(s,1H,C
4-H),δ6.46(s,1H,C
5-H),δ6.81(s,1H,C
2-H),δ7.65(s,1H,C
8-H);
EI-MS(m/z):316(M
+),299,287,270,185,83.
Embodiment 4
1,7-dihydroxyl-3, the preparation of 6-dimethoxy-9H-xanthone (VIII):
With 1,3,6,7-tetramethoxy xanthone (VII) 4.74g (0.015mol) is dissolved in the solvent of 45mL Hydrogen bromide and 55mL Glacial acetic acid min. 99.5; Nitrogen protection refluxed 1 hour is cooled to room temperature, in reaction solution impouring 150mL frozen water, leaves standstill the back suction filtration; Water successively, the saturated common salt water washing, purification by silica gel column chromatography behind the filtration cakes torrefaction (sherwood oil: ETHYLE ACETATE=10: 3), pale yellow powder shape solid 1; 7-dihydroxyl-3,6-dimethoxy-9H-xanthone (VIII) 2.80g, yield 65%.
1H-NMR(300MHz,CDCl
3):δ3.91(s,3H,C
3-OCH
3),δ4.11(s,3H,C
6-OCH
3),δ5.53(s,1H,C
7-OH),δ6.41(s,1H,C
4-H),δ6.44(s,1H,C
5-H),δ6.86(s,1H,C
2-H),δ7.66(s,1H,C
8-H),δ13.05(s,1H,C
1-OH);
EI-MS(m/z):288(M
+),273,259,169,141,85.
Embodiment 5
3,6-dimethoxy-1, the preparation of 7-two allyloxys-9H-xanthone (IX):
With 1,7-dihydroxyl-3,6-dimethoxy-9H-xanthone (VIII) 1.44g (0.005mol) is dissolved in the 40mL acetone; Add salt of wormwood 4.14g (0.03mol) successively, Soiodin 10mg, allyl bromide 98 1.73mL (0.02mol); Back flow reaction 12 hours, (the sherwood oil: ETHYLE ACETATE=2: 1), get yellow-white pulverulent solids 3 of column chromatography behind the suction filtration; 6-dimethoxy-1,7-two allyloxys-9H-xanthone (IX) 1.68g, yield 91.3%.
mp:135~137℃;
1H-NMR(300MHz,CDCl
3):δ3.67(d,J=6.12Hz,2H,-CH
2-),δ3.94(s,3H,C
3-OCH
3),δ4.16(s,3H,C
6-OCH
3),δ4.24(d,J=6.42Hz,2H,-CH
2-),δ5.12(d,J=9.22Hz,2H,=CH
2),δ5.43(d,J=7.43Hz,2H,=CH
2),δ6.23(m,1H,-CH=),δ6.33(m,1H,-CH=),δ6.44(s,1H,C
4-H),δ6.49(s,1H,C
5-H),δ7.10(s,1H,C
2-H),δ7.88(s,1H,C
8-H);
EI-MS(m/z):368(M
+),353,339,327,243,215.
Embodiment 6
3,6-dimethoxy-1,7-dihydroxyl-2, the preparation of 8-diallyl-9H-xanthone (X):
With 3,6-dimethoxy-1,7-two allyloxys-9H-xanthone (IX) 370mg (1mmol); N, N-Dimethylaniline15mL add in the 50mL two-neck bottle, and nitrogen protection heats up down; Refluxed 2 hours, and be cooled to room temperature, add 15% hydrochloric acid soln 30mL; Ethyl acetate extraction, saturated ammonium chloride solution washing, organic layer anhydrous sodium sulfate drying.Column chromatography purification (sherwood oil: ETHYLE ACETATE=4: 1), get the yellow needle-like solid 3 of product, 6-dimethoxy-1,7-dihydroxyl-2,8-diallyl-9H-xanthone (X) 320mg, yield 87%.
mp:197~198℃;
1H-NMR(300MHz,CDCl
3):δ3.40(d,J=6.22Hz,2H,-CH
2-),δ3.86(s,3H,C
3-OCH
3),δ4.01(s,3H,C
6-OCH
3),δ4.19(d,J=4.12Hz,2H,-CH
2-),δ4.94(m,4H,2-CH
2-),δ5.64(s,1H,C
7-OH),δ5.93(m,1H,-CH=),δ6.01(m,1H,-CH=),δ6.32(s,1H,C
4-H),δ6.75(s,1H,C
5-H),δ13.50(s,1H,C
1-OH);
Embodiment 7
3,6,7-trimethoxy-1-hydroxyl-2, the preparation of 8-diallyl-9H-xanthone (XI):
With 3,6-dimethoxy-1,7-dihydroxyl-2,8-diallyl-9H-xanthone (X) 368mg (1mmol) is dissolved in the 30mL acetone; Add salt of wormwood 276mg (2mmol), methyl-sulfate 0.142mL (1.5mmol), back flow reaction 2 hours; Dried organic solvent is revolved in decompression behind the suction filtration, and the sodium hydroxide solution 25mL of adding 10% refluxed 1 hour, was cooled to room temperature; Add about Hydrogen chloride adjust pH to 3, dichloromethane extraction three times, wash three times after anhydrous sodium sulfate drying.Column chromatographic isolation and purification (sherwood oil: ETHYLE ACETATE=8: 1), obtain yellow blocks of solid (XI) 350mg, yield 91.6%.
mp:167~168℃;
1H-NMR(300MHz,CDCl
3):δ3.38(d,J=6.12Hz,2H,-CH
2-),δ3.85(s,3H,C
3-OCH
3),δ4.04(s,3H,C
6-OCH
3),δ4.12(s,3H,C
7-OCH
3),δ4.26(d,J=10.12Hz,2H,-CH
2-),δ4.96(m,4H,2-CH
2-),δ5.96(m,1H,-CH=),δ6.01(m,1H,-CH=),δ6.36(s,1H,C
4-H),δ6.75(s,1H,C
5-H),δ13.09(s,1H,C
1-OH);
EI-MS(m/z):382(M
+),367,352,277,169,98,55.
Embodiment 8
The preparation of compound (XII):
With 3,6,7-trimethoxy-1-hydroxyl-2,8-diallyl-9H-xanthone (XI) 764mg (2mmol; 1eq) be dissolved in the 1.8mL THF, add 6mL water successively, the 6mL trimethyl carbinol, 36.8mg (0.1mmol; 0.05eq) two hydration potassium osmates, stir and add 2.14g after 0.5 hour (room temperature reaction is suction filtration after 8 hours for 10mmol, 5eq) sodium periodate; Remove solvent under reduced pressure, add the methylene dichloride dissolving, use saturated sodium sulfite solution, water washing successively; Organic layer is used anhydrous sodium sulfate drying, obtains compound (XII), stores for future use.
Embodiment 9
The preparation of bromo sec.-propyl triphenylphosphine:
3.1g isopropyl bromide (0.025mol) and 6.6g triphenylphosphine (0.025mol) add in the tube sealing of a band piston, are heated to 110 ℃, sealed reaction 12 hours; Be cooled to room temperature; Use ether: the solvent recrystallization of methyl alcohol=10: 3, white powder solid 6.8g, yield 70%.
Mp:235~237 ℃ (literature value: 238~239 ℃).
Embodiment 10
The preparation of triphenyl sec.-propyl phosphine alkane and the preparation of β-mangostin-OMe:
In the 100mL three-necked bottle, add 2.30g (6mmol) bromo sec.-propyl triphenylphosphine, THF 30mL, cryosel is bathed cooling under the nitrogen protection, drips the hexane solution of 3.0mL (2.4M) n-Butyl Lithium, is warming up to stirring at room 1 hour, gets dark red liquid.Place cryosel to bathe in the flask that fills the scarlet reaction solution, add the tetrahydrofuran solution of compound (XII), room temperature reaction 6 hours, ethyl acetate extraction behind the evaporated under reduced pressure solvent merges organic layer, washing, anhydrous sodium sulfate drying.Column chromatographic isolation and purification (sherwood oil: ETHYLE ACETATE=4: 1), obtain yellow needle-like solid 372mg, yield 42.4%.
mp:116~118℃;
1H-NMR(300MHz,CDCl
3):δ1.64(s,6H,2×-CH
3),δ1.79(s,3H,-CH
3),δ1.89(s,3H,-CH
3),δ3.34(d,J=9.12Hz,2H,-CH
2-),3.79~4.14(t,9H,-OCH
3),δ4.12(m,2H,-CH
2-),δ5.18(m,2H,2×-CH=),δ6.57(s,1H,C
4-H),δ6.73(s,1H,C
5-H),δ13.48(s,1H,C
1--OH);
EI-MS(m/z):438(M
+),423,409,367,277,199,77.
Embodiment 11
The preparation of α-mangostin:
At room temperature, compound β-mangostin-Ome 50mg is dissolved among the 1.5mLDMSO, adds the 100mg sodium cyanide; Nitrogen protection, mixed solution stirred 6 hours down at 150 ℃, poured in the frozen water after being cooled to room temperature; Use ethyl acetate extraction, use saturated copperas solution successively, water; The saturated common salt water washing, anhydrous sodium sulfate drying.Column chromatographic isolation and purification (sherwood oil: ETHYLE ACETATE=6: 1), obtain yellow solid α-mangostin 30mg, yield 64%.
mp:180-182℃;
1H-NMR(300MHz,CDCl
3):δ1.70,1.78,1.84,1.85(3H?each,s,CH
3?x?4),δ3.46,4.10(2Heach,d,J=7.0Hz,J=5.9Hz,-CH
2-),δ3.81(3H,s,C
7-O?CH
3),δ5.26-5.312H,m,(2×-CH=),δ6.30,6.83(1H?each,s,C
4,C
5-H),δ13.78(1H,s,C
1-OH);
HR-EIMS(m/z):410.1728.
Embodiment 12
The preparation of γ-mangostin:
Compound α-mangostin100mg is dissolved in the 2mL ethylene dichloride, adds the 1.0mL pyridine, stir down slowly adding aluminum chloride, add the Soiodin of catalytic amount, mixed-liquor return is stopped reaction after 3 hours.After being cooled to room temperature, reaction solution is poured in the mixture of Hydrogen chloride and frozen water, used ethyl acetate extraction, merge organic layer, transfer PH with triethylamine.Organic layer is water and saturated common salt washing successively, anhydrous sodium sulfate drying.Column chromatographic isolation and purification (sherwood oil: ETHYLE ACETATE=2: 1), obtain yellow solid γ-mangostin 57mg, yield 60%.
mp:207-210℃;
1H-NMR(600MHz,acetone-D
6):δ1.62,1.63(3H?each,s,H-5′H-5″),δ1.78(3H,s,H-4″),1.79(3H,s,H-4′),3.48(2H,d,J=7.2Hz,H-1″),3.92(3H,s,OCH
3),4.25(2H,d,J=6.0Hz,H-1′),5.40(2H,m,H-2′and?H-2″),6.53(1H,s,H-8),6.95(1H,s,H-1),13.92(1H,s,C
5-OH);
ESI-MS(m/z):409[M-H]
-.。
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110302040.8A CN102653533B (en) | 2011-10-09 | 2011-10-09 | Total synthesis method of mangostin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110302040.8A CN102653533B (en) | 2011-10-09 | 2011-10-09 | Total synthesis method of mangostin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102653533A true CN102653533A (en) | 2012-09-05 |
CN102653533B CN102653533B (en) | 2015-04-29 |
Family
ID=46729278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110302040.8A Expired - Fee Related CN102653533B (en) | 2011-10-09 | 2011-10-09 | Total synthesis method of mangostin |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102653533B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103319448A (en) * | 2013-04-02 | 2013-09-25 | 中国药科大学 | Xanthenone derivatives, and preparation method and applications thereof |
CN103709135A (en) * | 2013-12-23 | 2014-04-09 | 广西师范大学 | Xanthone derivative and preparation method and application thereof |
CN103864747A (en) * | 2014-03-28 | 2014-06-18 | 中国药科大学 | Novel synthesis method of mangostin |
CN103880807A (en) * | 2014-03-18 | 2014-06-25 | 杭州博麦医药科技有限公司 | Synthesis process of high-purity alpha-mangostin |
CN105503809A (en) * | 2015-12-29 | 2016-04-20 | 陕西嘉禾生物科技股份有限公司 | Synthetic method of gamma-mangostin |
CN106554341A (en) * | 2015-09-30 | 2017-04-05 | 南京美竹医药科技有限公司 | A kind of preparation method and purposes of mangostin and the like |
CN106977489A (en) * | 2017-04-20 | 2017-07-25 | 清华大学 | A kind of method for preparing polysubstituted xanthones derivative |
CN107857751A (en) * | 2017-12-18 | 2018-03-30 | 上海中医药大学 | A kind of compound and preparation method thereof, pharmaceutical composition and purposes |
CN113456824A (en) * | 2020-03-31 | 2021-10-01 | 四川大学华西医院 | Anti-tumor drug-loading nano composite material |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603213A (en) * | 1984-09-27 | 1986-07-29 | Ortho Pharmaceutical Corporation | Total synthesis of 1RS,4SR,5RS-4-(4,8-dimethyl-5-hydroxy-7-nonen-1-yl)-4-methyl-3,8-dioxabicyclo[3.2.1]octane-1-acetic acid |
JP2004042428A (en) * | 2002-07-11 | 2004-02-12 | Konica Minolta Holdings Inc | Image forming method and ink jet recording equipment used therefor |
JP2007153773A (en) * | 2005-12-02 | 2007-06-21 | Shiseido Co Ltd | Xanthone derivative, and skin care preparation and pharmaceutical composition each containing the same |
CN101955475A (en) * | 2010-05-25 | 2011-01-26 | 苏州派腾生物医药科技有限公司 | Preparation method of alpha-mangostin |
-
2011
- 2011-10-09 CN CN201110302040.8A patent/CN102653533B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4603213A (en) * | 1984-09-27 | 1986-07-29 | Ortho Pharmaceutical Corporation | Total synthesis of 1RS,4SR,5RS-4-(4,8-dimethyl-5-hydroxy-7-nonen-1-yl)-4-methyl-3,8-dioxabicyclo[3.2.1]octane-1-acetic acid |
JP2004042428A (en) * | 2002-07-11 | 2004-02-12 | Konica Minolta Holdings Inc | Image forming method and ink jet recording equipment used therefor |
JP2007153773A (en) * | 2005-12-02 | 2007-06-21 | Shiseido Co Ltd | Xanthone derivative, and skin care preparation and pharmaceutical composition each containing the same |
CN101955475A (en) * | 2010-05-25 | 2011-01-26 | 苏州派腾生物医药科技有限公司 | Preparation method of alpha-mangostin |
Non-Patent Citations (7)
Title |
---|
《Tetrahedron Letters》 20020131 Kazuhiko Iikubo,等 The first direct synthesis of alpha-mangostin, a potent inhibitor of the acidic sphingomyelinase 291-293 1-4 第43卷, 第2期 * |
GEORGIOS VASSILIKOGIANNAKIS,等: "A New [2 + 2] Functionalization of C60 with Alkyl-Substituted 1,3-Butadienes: A Mechanistic Approach. Stereochemistry and Isotope Effects", 《J. AM. CHEM. SOC.》 * |
KAZUHIKO IIKUBO,等: "The first direct synthesis of α-mangostin, a potent inhibitor of the acidic sphingomyelinase", 《TETRAHEDRON LETTERS》 * |
王平 等: "Wittig反应研究进展", 《科技信息》 * |
赵佳: "山竹黄酮的提取、合成、分析及性质研究", 《西北大学硕士学位论文》 * |
路浩: "呫吨酮类衍生物的合成与体外抗氧化活性研究", 《大连理工大学硕士学位论文》 * |
邱惊雷: "天然产物Malabaricone C的全合成研究", 《四川大学硕士学位论文》 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103319448A (en) * | 2013-04-02 | 2013-09-25 | 中国药科大学 | Xanthenone derivatives, and preparation method and applications thereof |
CN103319448B (en) * | 2013-04-02 | 2016-04-27 | 中国药科大学 | A kind of Xanthone derivative and Synthesis and applications thereof |
CN103709135A (en) * | 2013-12-23 | 2014-04-09 | 广西师范大学 | Xanthone derivative and preparation method and application thereof |
CN103709135B (en) * | 2013-12-23 | 2016-08-17 | 广西师范大学 | Ton ketone derivatives and its preparation method and application |
CN103880807B (en) * | 2014-03-18 | 2016-09-28 | 杭州博麦医药科技有限公司 | The synthesis technique of high-purity alpha-mangostin |
CN103880807A (en) * | 2014-03-18 | 2014-06-25 | 杭州博麦医药科技有限公司 | Synthesis process of high-purity alpha-mangostin |
CN103864747B (en) * | 2014-03-28 | 2016-06-22 | 中国药科大学 | The total synthesis method of mangostin |
CN103864747A (en) * | 2014-03-28 | 2014-06-18 | 中国药科大学 | Novel synthesis method of mangostin |
CN106554341A (en) * | 2015-09-30 | 2017-04-05 | 南京美竹医药科技有限公司 | A kind of preparation method and purposes of mangostin and the like |
CN106554341B (en) * | 2015-09-30 | 2019-05-21 | 南京美竹医药科技有限公司 | The preparation method and purposes of a kind of mangostin and the like |
CN105503809A (en) * | 2015-12-29 | 2016-04-20 | 陕西嘉禾生物科技股份有限公司 | Synthetic method of gamma-mangostin |
CN106977489A (en) * | 2017-04-20 | 2017-07-25 | 清华大学 | A kind of method for preparing polysubstituted xanthones derivative |
CN107857751A (en) * | 2017-12-18 | 2018-03-30 | 上海中医药大学 | A kind of compound and preparation method thereof, pharmaceutical composition and purposes |
CN113456824A (en) * | 2020-03-31 | 2021-10-01 | 四川大学华西医院 | Anti-tumor drug-loading nano composite material |
CN113456824B (en) * | 2020-03-31 | 2023-03-31 | 四川大学华西医院 | Anti-tumor drug-loading nano composite material |
Also Published As
Publication number | Publication date |
---|---|
CN102653533B (en) | 2015-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102653533A (en) | Total synthesis method of mangostin | |
JPS6122046A (en) | Stilbene derivative | |
CN106905284B (en) | A kind of catalysis oxidation synthetic method of miscellaneous anthracene ketone compounds | |
CN113735847A (en) | Synthetic preparation method of berberine hydrochloride | |
CN112608296B (en) | Synthesis method of Brazilane natural product Brazilane | |
WO2001060774A1 (en) | Synthesis of resveratrol | |
Dolson et al. | A novel methoxy-directed ketal hydrolysis and its application to a convergent, regiospecific synthesis of (.+-.)-daunomycinone | |
CN108864160A (en) | The preparation method of boron-containing small molecules | |
CN106146457B (en) | 5-chloro-2-acyl chloride thiophene intermediate and preparation method thereof | |
CN105153083B (en) | Preparation method for polysubstituted furan compound | |
CN103058828A (en) | Synthetic method of 3,5-dyhydroxy alkylbenzene protected through alkyl group | |
CN101195575A (en) | Preparation method of (E)-3,5-dimethoxy-4'-acetoxystilbene | |
CN102180773B (en) | A kind of preparation method of resveratrol | |
CN102001979A (en) | Preparation method of 2-(2', 2'-difluoroethoxyl)-6-trifluoromethyl phenyl propyl sulfide | |
CN103864747B (en) | The total synthesis method of mangostin | |
CN101792451A (en) | Total synthesis method of 4 ', 5' -dihydroxy-5-methoxy- [6 ', 6' -dimethylpyran (2 ', 3': 7,8) ] coumarone chromone | |
Caprio et al. | Synthesis of novel chromeno [3, 4-b] pyridinones | |
WO2003095424A1 (en) | Process for producing shogaol and intermediates for the synthesis thereof | |
CN102190569B (en) | Method for preparing Prasugrel intermediate alpha-cyclopropylcarbonyl-2-fluorobenzyl bromide | |
McKittrick et al. | Natural benzofurans: synthesis of the arylbenzofuran constituents of Sophora tomentosa | |
CN111646972B (en) | Preparation method of selective estrogen receptor degradation agent and intermediate thereof | |
JP2021176823A (en) | Method for Producing Dibenzo [g, p] Chrysene Derivatives and Novel Dibenzo [g, p] Chrysene Derivatives | |
Wu et al. | A novel and convenient method for the synthesis of phenstatin | |
CN106632158B (en) | The preparation method of 7 β, 10 β-dimethoxy -10- deacetylate Baccatine IIIs | |
CN110452199B (en) | Preparation method of feloxicib |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150429 |
|
CF01 | Termination of patent right due to non-payment of annual fee |